TY - JOUR
T1 - Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [ 18F]fluorodeoxyglucose and neuropsychological testing
AU - Gilman, Sid
AU - Koeppe, Robert A.
AU - Little, Roderick
AU - An, Hyonggin
AU - Junck, Larry
AU - Giordani, Bruno
AU - Persad, Carol
AU - Heumann, Mary
AU - Wernette, Kris
N1 - Funding Information:
This study was supported in part by NIH grants P50 AG08671 from the National Institute of Aging and P01 NS15655 from the National Institute of Neurological Disorders and Stroke.
PY - 2005/2
Y1 - 2005/2
N2 - We compared the relative utility of neuropsychological testing and positron emission tomography (PET) with [ 18F]fluorodeoxyglucose ([ 18F]FDG) in differentiating Alzheimer's disease (AD) from dementia with Lewy bodies (DLB). We studied 25 patients with AD, 20 with DLB, and 19 normal elderly controls. There was no difference between patient groups for MMSE, confrontational naming, or verbal learning. The DLB group was significantly more impaired than the AD group for verbal fluency, and the AD group was significantly more impaired than the DLB group for verbal delayed recall. The DLB group had greater difficulty than the AD group on a visual discrimination task that does not require motor functioning, but the difference did not reach significance. Family ratings of motor functioning suggested significantly greater impairment in DLB patients than in AD patients. PET studies revealed significantly lower local cerebral metabolic rates for glucose (lCMRglc) for visual cortex (Brodmann areas 17, 18, and 19) in the DLB than the AD group, but no differences for other regions commonly affected in AD, including posterior cingulate, superior parietal lobe, lateral temporal lobe, and the prefrontal region. Motor ratings were significantly correlated with lCMRglc in all areas of cerebral cortex, including Brodmann areas 17, 18, and 19. The results demonstrate a similar profile of cerebral hypometabolism in the two patient groups except in the visual cortex, where the DLB group shows markedly lower lCMRglc than the AD group. Neuropsychological testing also differentiates the groups, and family ratings of motor functioning are as robust as PET in these later stages of the disorders.
AB - We compared the relative utility of neuropsychological testing and positron emission tomography (PET) with [ 18F]fluorodeoxyglucose ([ 18F]FDG) in differentiating Alzheimer's disease (AD) from dementia with Lewy bodies (DLB). We studied 25 patients with AD, 20 with DLB, and 19 normal elderly controls. There was no difference between patient groups for MMSE, confrontational naming, or verbal learning. The DLB group was significantly more impaired than the AD group for verbal fluency, and the AD group was significantly more impaired than the DLB group for verbal delayed recall. The DLB group had greater difficulty than the AD group on a visual discrimination task that does not require motor functioning, but the difference did not reach significance. Family ratings of motor functioning suggested significantly greater impairment in DLB patients than in AD patients. PET studies revealed significantly lower local cerebral metabolic rates for glucose (lCMRglc) for visual cortex (Brodmann areas 17, 18, and 19) in the DLB than the AD group, but no differences for other regions commonly affected in AD, including posterior cingulate, superior parietal lobe, lateral temporal lobe, and the prefrontal region. Motor ratings were significantly correlated with lCMRglc in all areas of cerebral cortex, including Brodmann areas 17, 18, and 19. The results demonstrate a similar profile of cerebral hypometabolism in the two patient groups except in the visual cortex, where the DLB group shows markedly lower lCMRglc than the AD group. Neuropsychological testing also differentiates the groups, and family ratings of motor functioning are as robust as PET in these later stages of the disorders.
KW - Alzheimer's disease
KW - Dementia with Lewy bodies
KW - Local cerebral metabolic rate for glucose
KW - Magnetic resonance imaging
KW - Neuropsychological testing
KW - Positron emission tomography
KW - [ F]fluorodeoxyglucose
UR - http://www.scopus.com/inward/record.url?scp=11444270025&partnerID=8YFLogxK
U2 - 10.1016/j.expneurol.2004.06.017
DO - 10.1016/j.expneurol.2004.06.017
M3 - Article
C2 - 15629765
AN - SCOPUS:11444270025
SN - 0014-4886
VL - 191
SP - S95-S103
JO - Experimental Neurology
JF - Experimental Neurology
IS - SUPPL. 1
ER -